Message de service : ce billet est le dernier numero d’Onco Actu redige par son createur

Deciding qualification and you may checking out the loan application process will likely be an elaborate fling
6 maja, 2022
FW ran for someone completely different than just myself
6 maja, 2022

Message de service : ce billet est le dernier numero d’Onco Actu redige par son createur

Message de service : ce billet est le dernier numero d’Onco Actu redige par son createur

Fideles lecteurs, sachez que je pars a la retraite fier d’avoir contribue, durant toutes ces annees, a la lutte contre les cancers en France. Gerard Chevalier

Why the ban on nicotine vape fluid will do more harm than good [The Conversation] Last week the federal government’s Office of Drug Control announced changes to the importation of nicotine-containing electronic cigarette fluids that will seriously affect the estimated 227,000 regular e-cigarette users in Australia.

FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional [FDA] Today, the U

Yale Cancer Center Study Validates Combination Therapy for Aggressive Endometrial Cancer [Yale] Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research.

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer [FDA] The FDA’s approval for this indication was based on the results of one multicenter, international, open-label, active-controlled, randomized trial that compared Keytruda with chemotherapy treatment in 307 patients with MSI-H or dMMR metastatic colorectal cancer.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells [University of Illinois] “We realized that because this receptor binds both to the protein and the sugar on the surface of the cancer cell, there might be room to change the antibody so that it can bind to more than one protein attached to the short sugar,” Sharma said. “This could make it broadly reactive to different kinds of cancers.”

What to expect from ‘Modernizing the FDA’s Data Strategy’ meeting [STAT] There will also be many implications for the agency when the European Union’s General Data Protection Regulation and other similar regulations come into play. Privacy must be paramount as the data modernization strategy progresses.

EMA revises methodological guidance for trials impacted by COVID-19 [RAPS] The agency also says it will extend its decision to hold all upcoming committee and working party meetings virtually through . The agency adds that it will continue its practice of holding stakeholder events virtually or postponing them.

Roche’s combo therapy for advanced breast cancer gets U.S. FDA approval [Reuters] The therapy, which is initially used in combination with chemotherapy, can continue to be administered at home by a qualified healthcare professional after the patient is finished with the chemotherapy regimen.

Roche Gets FDA OK for Injectable Version of Breast Cancer Drug [Xconomy] The newly approved drug, Phesgo, is a fixed-dose mix of pertuzumab (Perjeta) and trastuzumab (Herceptin) that uses technology developed by San Diego’s Halozyme Therapeutics http://www.datingranking.net/fr/caribbean-cupid-review/.

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 [Novartis] Lung cancer is the most common type of cancer in Japan and approximately 3,000 patients are diagnosed with METex14 metastatic NSCLC, a particularly aggressive form of the disease, in Japan each year.

S. Food and Drug Administration approved Phesgo-a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf-for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer

NICE knocks back Janssen’s Zytiga combo for newly diagnosed, hormone-sensitive metastatic prostate cancer [Pharmafile] This is despite trial data supplied in support of the NICE application showing that patients receiving the Zytiga combo survived for a median of 53.3 months overall, compared to 36.5 months with placebo plus ADT.

Comments are closed.